Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NORTHWEST BIOTHERAPEUTICS INC

Get SEC filing alerts via email and in your feed for NORTHWEST BIOTHERAPEUTICS INC

NWBO

NORTHWEST BIOTHERAPEUTICS INC

About NORTHWEST BIOTHERAPEUTICS INC

Northwest Biotherapeutics is a biotechnology company specializing in personalized immune therapies for cancer. Its platform, DCVax, uses a patient’s own dendritic cells to target solid tumors, with products like DCVax-L for surgically removable cancers and DCVax-Direct for inoperable tumors. The company focuses on immunotherapy development, manufacturing, and regulatory approval, primarily serving cancer patients worldwide. It emphasizes innovation, patent protection, and strategic collaborations in the competitive cancer treatment market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NORTHWEST BIOTHERAPEUTICS INC

1
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports $3.1M Net Loss in Q1 2026, Improved Financial Position

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports $60.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports $26.8 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports Q2 2025 Financial Results with $15.4M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports $19.3 Million Net Loss in Q1 2025, Revenue Increases to $375,000

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports $83.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
NORTHWEST BIOTHERAPEUTICS INC Northwest Biotherapeutics Reports Significant Revenue Growth, But Continues to Face Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments